Skip to main content
Paula Busse, MD, Allergy & Immunology, New York, NY, The Mount Sinai Hospital

PaulaJBusseMD

Allergy & Immunology New York, NY

Assistant Professor, Medicine, Icahn School of Medicine

Dr. Busse is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Busse's full profile

Already have an account?

Education & Training

  • Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount SinaiFellowship, Allergy and Immunology, 1999 - 2001
  • Icahn School of Medicine at Mount Sinai/Mount Sinai Hospital
    Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1996 - 1999
  • University of Rochester School of Medicine and Dentistry
    University of Rochester School of Medicine and DentistryClass of 1996

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1997 - 2026

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
  • Fellow (FAAAAI) American Academy of Allergy Asthma and Immunology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Effect of Lanadelumab Compared with Placebo on Prevention of Hereditary Angioedema Attacks  
    Jonathan A Bernstein, Lawrence B Schwartz, Andrew M Smith, H James Wedner, Daniel Soteres, Timothy Craig, Douglas T Johnston, Aleena Banerji, Paula J Busse, William R ..., JAMA

Press Mentions

  • Interim Phase 4 Data Support TAKHZYRO® (Lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients
    Interim Phase 4 Data Support TAKHZYRO® (Lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema PatientsFebruary 28th, 2022
  • $70m from NIAID to Establish Trial Site Network Focusing on Childhood Asthma in Low-Income Urban Communities
    $70m from NIAID to Establish Trial Site Network Focusing on Childhood Asthma in Low-Income Urban CommunitiesApril 26th, 2021
  • Children’s National Hospital Becomes Part of the National CAUSE Clinical Research Network Under a $3 Million Grant
    Children’s National Hospital Becomes Part of the National CAUSE Clinical Research Network Under a $3 Million GrantApril 26th, 2021
  • Join now to see all

Grant Support

  • Contribution Of Tnf-Alpha To Mucus Cell Production In AsthmaNational Institute Of Allergy And Infectious Diseases2010
  • C1 Esterase Inhibitor As Treatment And Prevention In Hereditary AngioedemaNational Center For Research Resources2009
  • Contribution Of Tnf-Alpha To Mucus Cell Production In AsthmaNational Institute Of Allergy And Infectious Diseases2006–2009
  • Change TrialNational Center For Research Resources2008
  • Efficacy And Safety Of Purified C1 Esterase Inhibitor For Treatment Of HaeNational Center For Research Resources2006–2007
  • An Ascending Four-Dose Placebo Controlled Study To Assess The Efficacy And To...National Center For Research Resources2004

Professional Memberships

Hospital Affiliations